Markus Zettl

Markus Zettl

Company: Pieris Pharmaceuticals GmbH

Job title: Senior Director of Immuno–Oncology


The Use of Biomarkers to Confirm Mode of Action & Inform Combination Strategy for PRS-343 in Her2-Low Gastric Cancer in Combination with Tucatinib 11:30 am

PRS-343, the first bispecific to enter the clinic engineered to specifically activate 4-1BB in the tumor microenvironment is well tolerated and demonstrated durable anti-tumor activity in heavily pre-treated patient population including patients with “cold” tumors Biomarkers confirm the mode of action of PRS-343 with a clear dose-dependent increases in CD8+ T cells in the tumor…Read more

day: Track B - Day 2 AM

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.